Efficacy and safety of aprotinin in aortocoronary bypass and valve replacement operations: a placebo-controlled randomized double-blind study

Abstract

To assess the efficacy and safety of the use of a high-dose regimen of aprotinin in routine cardiac operations, a placebo-controlled randomized double- blind study was conducted in 93 adult patients undergoing cardiopulmonary bypass. Aprotinin-treated patients (group A, n = 46) received 2 × 10⁶ Kallikrein Inactivating Units (KIU) of aprotinin before incision, 2 × 10⁶ KIU in the priming solution and 5 x 105 KIU/h during CPB. Control patients (group B, n = 47) received the same volume of normal saline.

Mean postoperative blood loss in ml after six hours and in total until removal of thoracic drains decreased significantly from 752 and 1933 in controls, to 358 and 1051 in treated patients (p < 0.001). Mean total transfusion needs were 2.6 (A) and 4.8 (B) units per patient. Adverse events were evenly distributed between both groups and could not be attributed to aprotinin use. We, therefore, recommend the use of a high-dose regimen of aprotinin for routine cardiac operations despite its cost.

Get full access to this article

View all access options for this article.

References

Fritz H. , Wunderer G. Biochemistry and applications of aprotinin, the kallikrein inhibitor from bovine organs. Arzneim-Forsch Drug Res 1983 ; 33: 479-94.

Royston D. , Bidstrup BP , Taylor KM , Sapsford SN Effect of aprotinin on the need for blood transfusion after repeat open heart surgery. Lancet 1987; ii: 1289-91.

van Oeveren W. , Jansen NJ , Bidstrup BP et al. Effects of aprotinin on hemostatic mechanisms during cardiopulmonary bypass. Ann Thorac Surg 1987; 44: 640-45.

Harker LA , Malpass TW , Branson HE , Hessel EA , Slichter SJ Mechanism of abnormal bleeding in patients undergoing cardiopulmonary bypass: acquired transient platelet dysfunction associated with selective alpha-granule release. Blood 1980; 56: 824-34.

Kaplan AP , Silverberg M. The coagulation-kinin pathway of human plasma. Blood 1987; 70: 1-5.

Havert J. , Nicoloso G. , Schleuning WD , Bachmann F. , Schapira M. Plasminogen activators in dextran sulfate-activated euglobulin fractions: a molecular analysis of factor XII and prekallikrein dependent fibrinolysis . Blood 1989; 73: 994-99.

van Oeveren W. , Eijsman L. , Roozendaal KJ , Wildevuur Crh. Platelet preservation by aprotinin during cardiopulmonary bypass. Lancet 1988; i: 644.

Huiming Huang, Wenxiang Ding , Zhaohang Su, Weizhnong Zhang. Mechanism of the preserving effect of aprotinin on platelet function and its use in cardiac surgery. J Thorac Cardiovasc Surg 1993; 106: 11-18.

Royston D. High-dose aprotinin therapy: a review of the first five years' experience . J Cardiothorac Vasc Anesth 1992; 6: 76-100.

10.

Bidstrup BP , Royston D. , Taylor KM , Sapsford RN Reduction in blood loss and blood use after cardiopulmonary bypass with high dose aprotinin (Trasylol). J Thorac Cardiovasc Surg 1989 ; 97: 364-72.

11.

Friedrich G. , Weber C. , Bernard C. , Hettwer A. , Schlosser V. Reduction of blood transfusion requirement in open heart surgery by administration of high doses of aprotinin - preliminary results. Thorac Cardiovasc Surg 1989; 37: 89-91.

12.

Dietrich W. , Baranhay A. , Dilthey G. et al. Reduction of homologous blood requirement in cardiac surgery by intraoperative aprotinin application - clinical experience in 152 cardiac surgical patients. Thorac Cardiovasc Surg 1989; 37: 92-98.

13.

Alajmo F. , Calamai G. , Perna AM et al. High dose aprotinin: hemostatic effects in open-heart operations . Ann Thorac Surg 1989; 48: 536-39.

14.

van Oeveren W. , Harder MP , Roozendaal KJ , Eijsman L. , Wildevuur Crh. Aprotinin protects platelets against the initial effect of cardiopulmonary bypass. J Thorac Cardiovasc Surg 1990; 99: 788-97.

15.

Royston D. , Bidstrup BP , Taylor KM , Sapsford RN Aprotinin reduces bleeding after open heart surgery in patients taking aspirin and those with renal failure. Anesthesiology 1989; 71: A6.

16.

Bidstrup BP , Royston D. , McGuiness C. , Sapsford RN Aprotinin in aspirin-pretreated patients. Perfusion 1990 ; 5(suppl): 77-81.

17.

Murkin JM , Lux J. , Shannon NA et al. Aprotinin significantly decreases bleeding and transfusion requirements in patients receiving aspirin and undergoing cardiac operations. J Thorac Cardiovasc Surg 1994; 107: 554-61.

18.

Cosgrove DM Use of aprotinin in repeat myocardial revascularization: Cleveland Clinic experience. Perfusion 1993; 8(suppl): 36-42.

19.

Lemmer JH , Stanford W. , Bonney SL et al. Aprotinin for coronary bypass operations: efficacy, safety, and influence on early saphenous vein graft patency. J Thorac Cardiovasc Surg 1994; 107: 543-53.

20.

Freeman JG , Turner GA , Venables CW , Latner AL Serial use of aprotinin and incidence of allergic reactions. Curr Med Res Opin 1983; 8: 559-61.

21.

Royston D. , Bidstrup BP , Sapsford RN , Taylor KM Reduced blood loss after open heart surgery with aprotinin is associated with an increase in the activated clotting time. J Cardiothorac Anesth 1989; 3 (5, suppl 1): 80.

22.

Baele PL , Ruiz-Gomez J. , Londot C. , Sauvage M. , Van Dijck MJ , Robert A. Systematic use of aprotinin in cardiac surgery: influence on total homologous exposure and hospital cost. Acta Anaesth Belg 1992; 43: 103-12.